Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at UC Irvine UCSF
Dates
study started
completion around

Description

Summary

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.

Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA.

The study is looking at several other research questions, including:

  • Side effects that may be experienced from taking vonsetamig
  • How vonsetamig works in the body
  • How much vonsetamig is present in the blood
  • If vonsetamig works to lower levels of antibodies to HLA

Official Title

A Dose Escalation and Proof-of-Concept Study of Vonsetamig (BCMA × CD3 Bispecific Antibody) for Desensitization of Chronic Kidney Disease Patients in Need of Kidney Transplantation Who Are Highly Sensitized to Human Leukocyte Antigen

Keywords

Chronic Kidney Disease (CKD), Kidney Transplant, Hemodialysis, Desensitization, Human Leukocyte Antigen (HLA), Kidney Diseases, Chronic Renal Insufficiency, Vonsetamig

Eligibility

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • Connie Frank Transplant Center at UCSF accepting new patients
    San Francisco California 94143 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT05092347
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 56 study participants
Last Updated